Cadonilimab in Locally Advanced MSI-H/dMMR Colorectal Cancer
This is a two-arm phase II clinical study to evaluate the efficacy and safety of Cadonilimab (a PD-1/CTLA-4 bispecific antibody) in MSI-H/dMMR locally advanced colorectal cancer as the regimen of neoadjuvant treatment. Eligible patients will receive Cadonilimab monotherapy for eight cycles before surgery and part of patients may exempt from surgery.
dMMR Colorectal Cancer
DRUG: Cadonilimab
complete response rate, For colon cancer arm, complete response rate include the rate of pathological complete response and clinical complete response; for rectal cancer arm, complete response rate means the rate of clinical complete response, 3 years
OS, Overall survival, From date of initiation of treatment to date of death due to any cause, assessed up to 3 years|DFS, Disease free survival, From date of initiation of treatment to date of progression or death due to any cause, whichever occurs first, assessed up to 3 years|pCR rate, The rate of pathologic complete response for patients receiving surgery, 2 year
This is a two-arm phase II clinical study to evaluate the efficacy and safety of Cadonilimab (a PD-1/CTLA-4 bispecific antibody) in MSI-H/dMMR locally advanced colorectal cancer as the regimen of neoadjuvant treatment. Eligible patients will receive Cadonilimab monotherapy for eight cycles before surgery and part of patients may exempt from surgery.